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MaBACKGROUND It is unclear whether achieving multiple risk factor (RF) goals through protocol-guided intensive
medical therapy is feasible or improves outcomes in type 2 diabetes mellitus.
OBJECTIVES This study sought to quantify the relationship between achieved RF goals in the BARI 2D (Bypass
Angioplasty Investigation Revascularization 2 Diabetes) trial and cardiovascular events/survival.
METHODS We performed a nonrandomized analysis of survival/cardiovascular events and control of 6 RFs (no smoking,
non–high-density lipoprotein cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure [systolic <130 mm Hg;
diastolic <80 mm Hg], glycosylated hemoglobin <7%) in BARI 2D. Cox models with time-varying number of RFs in
control were adjusted for baseline number of RFs in control, clinical characteristics, and trial randomization assignments.
RESULTS In 2,265 patients (mean age 62 years, 29% women) followed up for 5 years, the mean  SD number of RFs in
control improved from 3.5  1.4 at baseline to 4.2  1.3 at 5 years (p < 0.0001). The number of RFs in control during the
trial was strongly related to death (global p ¼ 0.0010) and the composite of death, myocardial infarction, and stroke
(global p ¼ 0.0035) in fully adjusted models. Participants with 0 to 2 RFs in control during follow-up had a 2-fold higher
risk of death (hazard ratio: 2.0; 95% conﬁdence interval: 1.3 to 3.3; p ¼ 0.0031) and a 1.7-fold higher risk of the composite
endpoint (hazard ratio: 1.7; 95% conﬁdence interval: 1.2 to 2.5; p ¼ 0.0043), compared with those with 6 RFs in control.
CONCLUSIONS Simultaneous control of multiple RFs through protocol-guided intensive medical therapy is feasible
and relates to cardiovascular morbidity and mortality in patients with coronary disease and type 2 diabetes mellitus.
(Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305) (J Am Coll Cardiol
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767cardiovascular event rates among patients with coro-
nary heart disease (CHD) and T2DM in the BARI 2D
(Bypass Angioplasty Revascularization Investigation
2 Diabetes) trial.SEE PAGE 774
CHD = coronary heart disease
CVD = cardiovascular disease
HbA1c = glycosylated
hemoglobin
MI = myocardial infarction
non-HDL-C = non-high-
density lipoprotein cholesterol
RF = risk factor
T2DM = type 2 diabetes
mellitusMETHODS
BARI 2D DESIGN, ENROLLMENT, AND FOLLOW-UP. The
BARI 2D protocol and study results have been
described previously (6–8). Brieﬂy, this study
enrolled patients with T2DM and angiographically
documented stable CHD. Using a 2  2 factorial
design, patients were randomized simultaneously to
undergo cardiac treatment and glycemic control
treatment strategies. The randomized cardiac treat-
ment strategies entailed intensive medical therapy
with revascularization within 4 weeks or intensive
medical therapy with revascularization when clini-
cally indicated. The randomized glycemic control
strategies compared primarily insulin-sensitizing
versus primarily insulin-providing treatments. The
study was approved by the local institutional review
boards, and subjects provided informed consent. The
current post-hoc analysis includes 2,265 of the 2,368
BARI 2D patients (103 patients were missing RF
information).
Target levels for RFs were adjusted as practice
guidelines evolved. The ﬁnal targets, collection fre-
quency, and core laboratory status for key RFs in the
BARI 2D protocol are shown in Table 1. Non–high-
density lipoprotein cholesterol (non-HDL-C) rather
than low-density lipoprotein cholesterol was chosen
for analysis on the basis of pathophysiological and
statistical considerations. Patients were followed up
until their 6-year visit or December 2008, whichever
came earlier.
RF MANAGEMENT. Cardiovascular RF management
followed a detailed protocol (8) and includedTABLE 1 RF Target Levels and Collection Details
Target
Systolic BP <130 mm Hg Mon
Diastolic BP <80 mm Hg Mon
Smoking status Nonsmoker Ann
HbA1c <7% Bas
TG <150 mg/dl (<1.70 mmol/l) Bas
Non–HDL-C <130 mg/dl (<3.37 mmol/l)
Optional goal: <100 mg/dl (<2.59 mmol/l)
Bas
BP ¼ blood pressure; HbA1c ¼ glycosylated hemoglobin; non-HDL-C ¼ non-high-densitmonitoring and regular feedback on smoking
cessation, dietary and exercise advice, and
protocol-guided pharmacological manage-
ment for dyslipidemia, hyperglycemia, and
hypertension.
Of the 49,196 clinic visits in BARI 2D, a
total of 47,044 (95%) had up-to-date RF in-
formation for all 6 RFs. Visit information was
carried forward up to 15 months. Clinic visits
were included when all 6 RFs were measured
or up to date, with subjects contributing
when they had available RF data.
RF MODELING. The number of RFs in control
was modeled with 4 indicator variables (in
control categories of 0 to 2, 3, 4, and 5 [with 6 as the
reference]). RFs were in control if they met the tar-
gets listed in Table 1. In a secondary exploratory
analysis, we modeled a J-shaped relationship of blood
pressure (BP) and glycosylated hemoglobin (HbA1c)
with outcomes, as recent data suggest that overly
tight control might be associated with harm (9,10). In
this secondary analysis, systolic BP between 110
mm Hg and 140 mm Hg was in control and HbA1c
between 6.5% and 7.5% was in control. Values outside
these ranges were considered out of control.
We analyzed the relationship between the number
of RFs in control with all-cause death and with car-
diovascular disease (CVD) events (composite endpoint
of death, myocardial infarction [MI], or stroke).
STATISTICAL ANALYSIS. Baseline characteristics ac-
cording to the number of baseline RFs at goal were
compared by using an analysis of variance model for
continuous variables or chi-square tests for categorical
variables. At trial initiation, RFs were intensively
monitored and medication regimens intensiﬁed to
achieve RF targets, resulting in a large initial change
in RF control between baseline and year 1. We deter-
mined if subsequent RF control continued to improve,
was maintained, or declined from year 1 to year 5.Collection Frequency
Core
Laboratory
thly for ﬁrst 6 months, quarterly thereafter No
thly for ﬁrst 6 months, quarterly thereafter No
ually No
eline; months 1, 3, 6, and 20; and every
6 months thereafter
HbA1c core laboratory
eline, 6 months, then annually Lipid core laboratory
eline, 6 months, then annually Lipid core laboratory
y lipoprotein cholesterol; RF ¼ risk factor; TG ¼ triglycerides.
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quent changes (after year 1) were quantiﬁed by using a
generalized logistic estimating equation with a con-
tinuous follow-up year and a baseline visit indicator.
A signiﬁcant coefﬁcient for the baseline indicator
indicated a signiﬁcant ﬁrst-year change. The sign and
signiﬁcance of the coefﬁcient for year determined if
there was continued improvement, maintenance, or
degradation over the 5 years of follow-up.
Non–time-varying analyses used baseline or year 1
number of RFs in control, and time-varying RFs in
control during the trial were used in a separate anal-
ysis. Cox models were used to estimate the hazard
ratios and veriﬁed the proportional hazardTABLE 2 Baseline Characteristics
All Patients
(N ¼ 2,265)
0–2
(n ¼
Age, yrs 62  9 60 
Female 29 3
Nonwhite race 35 3
Geographical region
United States 62 5
Canada 15 1
Europe, South/Central America 22 3
Clinical characteristics
History of MI 32 28
History of heart failure 6
Cerebrovascular accident 10 9
Prior revascularization 24 2
No. of coronary lesions 5  2 5 
LVEF <50% 17 1
Myocardial Jeopardy Index 44  24 46 
Diabetes duration, yrs 10  9 10 
History of insulin use 29 30
Cardiovascular risk factors
Current cigarette smoker 12 26
BMI 32  6 32 
Systolic BP, mm Hg 132  20 145 
Diastolic BP, mm Hg 75  11 83 
TC, mg/dl 169  41 199 
HDL-C, mg/dl 38  10 37 
LDL-C, mg/dl 96  33 117 
TG, mg/dl 181  136 251 
Non–HDL-C, mg/dl 131  41 162 
HbA1c, % 7.6  1.6 8.5 
Trial strata
Insulin-sensitizing 50 50
Early revascularization 50 4
CABG 32 36
Values are mean  SD or %. To convert milligrams per deciliter to millimoles per lite
categories shown in the table may differ from 100% due to rounding. *In the baseline tab
reading. In the analysis, the RFs are modeled as 0 to 2, 3, 4, 5, and 6 RFs in control.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; HDL-C ¼ high-dens
ventricular ejection fraction; MI ¼ myocardial infarction; TC ¼ total cholesterol; other aassumption. All Cox models included baseline angio-
graphic information (number of total lesions,
Myocardial Jeopardy Index), baseline clinical and
demographic information (abnormal left ventricular
ejection fraction, prior revascularization, age, sex,
race/ethnicity, country), and randomization assign-
ment (insulin-sensitizing vs. insulin-providing,
prompt revascularization vs. medical therapy), and
revascularization strata (coronary artery bypass
grafting or percutaneous coronary intervention). A
Wald test determined if the number of RFs in control
was signiﬁcant overall.
All analyses were conducted by using SAS version
9.3 (SAS Institute, Inc., Cary, North Carolina).No. of RFs at Goal*
p Value
RFs
536)
3–4 RFs
(n ¼ 1,121)
5–6 RFs
(n ¼ 608)
8 63  9 64  9 <0.0001
3 29 27 0.0730
7 35 36 0.1576
<0.0001
1 64 69
4 16 17
5 20 15
34 32 0.0359
5 6 8 0.1484
10 9 0.8491
2 24 25 0.5302
2 5  2 5  2 0.0755
5 16 20 0.0889
24 45  24 43  24 0.1797
8 11  9 10  9 0.1530
31 25 0.0186
11 4 <0.0001
6 32  6 31  6 0.1368
20 132  19 120  14 <0.0001
11 74  10 68  8 <0.0001
40 170  40 143  25 <0.0001
10 38  10 39  10 0.0002
35 96  33 81  22 <0.0001
167 185  134 115  57 <0.0001
38 132  39 104  22 <0.0001
1.5 7.7  1.6 6.8  1.3 <0.0001
50 50 0.9919
5 48 56 0.0012
33 29 0.0366
r, multiply by 0.02586 for cholesterol and by 0.01129 for TG. Percentages within
le, the numbers of RFs in control are grouped as 0 to 2, 3 to 4, and 5 to 6 for ease of
ity lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; LVEF ¼ left
bbreviations as in Table 1.
TABLE 3 Achievement of RF Goals Over Time
Proportion of Patients With RFs in Control (%)*
Initial Change
(Baseline to Year 1)
p Value
Subsequent Change
(Year 1 to Year 5)
p Value
Baseline
(N ¼ 2,265)
Year 1
(n ¼ 2,137)
Year 3
(n ¼ 1,949)
Year 5
(n ¼ 1,060)
Non–HDL-C 54 70 79 82 <0.0001 <0.0001
TG 50 57 60 64 0.0005 <0.0001
Systolic BP 49 56 62 62 0.0002 0.0009
Diastolic BP 68 69 73 77 0.59 0.0002
No smoking 87 90 91 92 0.0013 0.14
HbA1c 40 51 48 46 <0.0001 <0.0001
Meet all 6 goals 7 12 15 15 <0.0001 0.18
*RFs in control deﬁned as: non–HDL-C <130 mg/dl, triglycerides <150 mg/dl, SBP <130 mm Hg, DBP <80 mm Hg, HbA1c <7%, and no smoking.
DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure; other abbreviations as in Table 1.
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BASELINE CHARACTERISTICS. The mean  SD age
was 62  9 years, with 29% women, 35% nonwhite,
and a mean duration of T2DM of 10 years. Baseline
RFs and comorbidities are detailed in Table 2.
Younger patients and those outside North America
had fewer RFs in control. Between 40% and 68% of
patients met individual RF targets, and only 7%
met all 6 RF goals (Table 3).
CHANGES IN PHARMACOLOGICAL THERAPY AND
CARDIOVASCULAR RF CONTROL. The greatest
change in medication use occurred within the ﬁrst
year (Table 4). Use of aspirin and lipid-lowering and
antihypertensive drugs increased signiﬁcantly over
the ﬁrst year and was maintained in follow-up.
Changes in diabetes medications reﬂect the random-
ization to insulin-providing and insulin-sensitizingTABLE 4 Trial Medication Status
Baseline
(N ¼ 2,265)
Year 1
(n ¼ 2,137)
Year 3
(n ¼ 1,94
Lipid-lowering drugs* 79 98 99
Statins 75 93 96
Antihypertensive agents 95 99 99
ACE inhibitor or ARB 77 90 91
Beta-blocker 73 87 87
Aspirin 88 92 94
Diabetes drugs†
IS only 16 31 28
IP only 30 43 44
IS and IP 45 20 23
None 8 6 5
Values are %. *Lipid-lowering drugs include ﬁbrates, niacin, bile acid sequestrants, ome
included metformin and thiazolidinediones. Insulin-providing (IP) drugs included insulin a
Diabetes) trial, patients were randomized to initial IS or IP treatment strategies and were o
Subsequently, patients could take drugs from the other arm of the trial if HbA1c values
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker.strategies and use of medications outside their ran-
domized strategy for glucose control.
The mean number of RFs in control increased
from 3.5  1.4 at baseline to 4.2  1.3 after 5 years
(p < 0.0001). Except for diastolic BP, the percentage
of patients at target increased between baseline and
year 1 (Table 3). Improvements continued through
year 5 except for smokers (maintained) and HbA1c
(worsened). At 5 years, >74% of patients had $4 RFs
in control, but only 15% of patients achieved control
of all 6 RFs (Figure 1). Online Table 1 displays the
average values of RFs over time.
CLINICAL OUTCOMES. Mean follow-up time was
5.0  1.4 years. The analysis includes 47,044 visits
from 2,265 patients. There were 275 deaths, 254 in-
cident fatal or nonfatal MIs (excluding 13 MIs before
the ﬁrst visit with all 6 RFs measured), 65 strokes, and
491 CVD events (excluding the previously mentioned9)
Year 5
(n ¼ 1,060)
Initial Change
(Baseline to Year 1)
p Value
Subsequent Change
(Year 1 to Year 5)
p Value
97 <0.0001 0.58
94 <0.0001 0.13
98 <0.0001 0.11
90 <0.0001 0.26
87 <0.0001 0.61
92 <0.0001 0.78
23 <0.0001 <0.0001
45 <0.0001 0.347
28 <0.0001 <0.0001
4 <0.0001 0.02
ga-3 fatty acids, and cholesterol absorption inhibitors. †Insulin-sensitizing (IS) drugs
nd sulfonylurea. In the BARI 2D (Bypass Angioplasty Investigation Revascularization 2
ffered pharmacological therapy if glycosylated hemoglobin (HbA1c) values were>7%.
were >8%.
FIGURE 1 Distribution of the Number of RFs in Control: Baseline to Year 5
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The numbers of risk factors (RFs) in control are shown at baseline and for each year of the
trial. Over time, the proportion of participants with $4 RFs in control increased while the
proportion with fewer RFs in control declined.
TABLE 5 Hazard Rat
Control at Year 1 and
No. of RFs at goal at y
(n ¼ 1,994) time
ﬁrst event after y
0–2
3
4
5
6
Global p value
No. of RFs at goal, tim
RF control (n ¼ 2
time to ﬁrst even
randomization
0–2
3
4
5
6
Global p value
*RFs in control deﬁned as
HbA1c <7%, and no smok
lesions, abnormal LVEF, My
trial strata.
CI ¼ conﬁdence interval
abbreviations as in Tables
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77013 MIs). The 5-year Kaplan-Meier total mortality rate
was 11%, and the rate of CVD events was 22%.
OUTCOMES RELATED TO RF CONTROL AT BASELINE
AND YEAR 1. Among the 2,169 patients with baselineios for Death and CVD Events According to Number of RFs in
Time-Varying*
Death† Death/MI/Stroke†
HR 95% CI p Value HR 95% CI p Value
ear 1
to
ear 1
2.1 1.2–3.7 0.0069 1.7 1.1–2.6 0.0199
1.7 1.0–2.8 0.0366 1.3 0.9–2.0 0.1589
1.1 0.7–1.8 0.7443 0.8 0.5–1.2 0.2118
1.1 0.7–1.8 0.7311 0.8 0.6–1.3 0.3929
1.0 Reference — 1.0 Reference —
0.0056 <0.0001
e-varying
,265)
t after
2.0 1.3–3.3 0.0031 1.7 1.2–2.5 0.0043
1.3 0.9–2.0 0.2092 1.2 0.8–1.6 0.4071
1.1 0.8–1.7 0.6685 1.2 0.9–1.6 0.3239
0.8 0.5–1.2 0.2858 0.9 0.7–1.3 0.574
1.0 Reference — 1.0 Reference —
0.0010 0.0035
: non–HDL-C <130 mg/dl, TG <150 mg/dl, SBP <130 mm Hg, DBP <80 mm Hg,
ing. †Cox models adjusted for: baseline number of RFs in control, number of total
ocardial Jeopardy Index, prior revascularization, age, sex, race/ethnicity, country, and
; CVD ¼ cardiovascular disease; HR ¼ hazard ratio; MI ¼ myocardial infarction; other
1, 2, and 3.RF data, there was no relationship between the
number of RFs in control at baseline and subsequent
death (hazard ratios between 0.8 and 1.1; p ¼ 0.36)
or CVD events (hazard ratios between 1.0 and 1.3;
p ¼ 0.22). In contrast, RF control at year 1 was
strongly related to both outcomes after adjusting for
the number of RFs in control at baseline. Participants
with 0 to 2 RFs in control had approximately twice the
risk of death and 1.7 times the risk of the composite
outcome compared with participants with 6 RFs in
control (Table 5).
OUTCOMES RELATED TO TIME-VARYING RFs IN
CONTROL DURING THE TRIAL. The number of RFs in
control during the trial was strongly related to death
(global p ¼ 0.0010) and CVD event (global p ¼ 0.0035)
after adjusting for the number of baseline RFs in
control (Table 5). Patients with 0 to 2 RFs in control
during follow-up were twice as likely to die as those
with 6 RFs in control with similar results for CVD
events. The model suggested a J-shape: patients with
6 RFs in control had nonsigniﬁcantly higher risks of
death and the composite endpoint compared with
patients with 5 RFs in control.
EXPLORATORY ANALYSIS TO LOOK FOR POTENTIAL
HARMS OF INTENSIVE BP AND GLUCOSE CONTROL.
Table 6 displays hazard ratios as a function of the
number of RFs in control, with systolic BP and HbA1c
ranges modiﬁed to reﬂect less stringent control. The
uptick in risk with 6 RFs in control compared with 5
RFs in control was no longer evident, suggesting that
aggressive control of systolic BP or HbA1c is associated
with increased risk. Hazard ratios associated with 0 to
2, 3, 4, and 5 RFs in control were consistently higher
than in the main analysis (Central Illustration). Results
were consistent with variations in the modiﬁed target
ranges (Online Table 2). In analyses strati-
ﬁed according to cardiac randomization group, those
randomly assigned to revascularization within 4
weeks exhibited a trend of larger beneﬁt of RF con-
trol. However, the interaction between the treatment
assignment and the number of RFs in control was not
signiﬁcant for either outcome (Online Table 3).
Figure 2 shows the adjusted effect of individual
time-varying RF control status entered simulta-
neously into the same model on the outcomes of
death and CVD events. Signiﬁcant RFs for death
included smoking, high non–HDL-C, systolic BP (too
low), and HbA1c (too high). For CVD events, high non–
HDL-C and systolic BP outside the target range (too
low and too high) were signiﬁcant predictors. When
using a stepwise algorithm to identify the signiﬁcant
RFs, non–HDL-C and systolic BP outside the target
range remained in the model (Online Table 4).
TABLE 6 Hazard Ratios for Death and CVD Events According to Number of RFs In
Control/Within Target Range*
Death† Death/MI/Stroke†
HR 95% CI p Value HR 95% CI p Value
0–2 3.8 2.2–6.5 <0.0001 2.4 1.6–3.6 <0.0001
3 2.4 1.4–4.1 0.0009 2.0 1.3–2.8 0.00011
4 1.9 1.1–3.0 0.0142 1.6 1.1–2.3 0.0163
5 1.5 0.9–2.4 0.1365 1.4 1.0–2.1 0.0709
6 1.0 Reference — 1.0 Reference —
Global p value <0.0001 0.0005
*RFs in-control deﬁned as: non–HDL-C <130 mg/dl, TG <150 mg/dl, 110 mm Hg < SBP <140 mm Hg, DBP <80
mm Hg, 6.5% < HbA1c <7.5%, and no smoking. Note redeﬁnition of target range for SBP and HbA1c in this
exploratory analysis. †Cox models adjusted for baseline number of RFs in control, number of total lesions,
abnormal LVEF, Myocardial Jeopardy Index, prior revascularization, age, sex, race/ethnicity, country, and trial
strata.
Abbreviations as in Tables 1, 2, 3, and 5.
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771DISCUSSION
To our knowledge, this study is the ﬁrst among
patients with T2DM and CHD to show a strong
association between the number of RFs below pre-
determined target levels and clinical outcomes.
These observational data suggest that patients with
CHD and T2DM require multiple RF interventions,
including management of systolic BP and HbA1c, to
avoid undertreatment and overtreatment.
RF control among patients with T2DM and CHD has
improved, but treatment targets in effect during BARI
2D are often not achieved (3). The level of RF control
at baseline in BARI 2D was comparable to that of a
contemporary National Health and Nutrition Exami-
nation Survey cohort (3). Consistent with other trials
that included patients with diabetes and CHD
(4,5,11,12), BARI 2D data show that RF treatment goals
are achievable by using evidence-based, protocol-
guided therapy with dedicated personnel.
Prospective data on the beneﬁts of multifactorial
intervention in patients with diabetes are sparse. The
Steno-2 study compared outcomes in patients withCENTRAL ILLUSTRATION Cardiac RF Control Improves Su
Bittner, V. et al. J Am Coll Cardiol. 2015; 66(7):765–73.
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The number of risk factors (RFs) in control is plotted (A and B) against mo
deﬁned on the basis of the BARI 2D (Bypass Angioplasty Investigation R
RFs in control have a numerically higher risk of events than those with 5
pressures and glycosylated hemoglobin. A J-shape is no longer evident
interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.T2DM randomized to receive intensive management
of multiple RFs versus usual care. Patients with
intensively managed RFs had a 53% reduction in the
7-year risk for CVD events and a 46% reduction in
mortality after post-trial follow-up to 13 years (4,5).
The study was small (160 patients) and not designedrvival and Reduces Cardiovascular Events
B
D
rtality and (C and D) against cardiovascular disease events. In panels A and C, RFs in control are
evascularization 2 Diabetes) trial protocol (main analysis). A J-shape is evident: patients with 6
RFs in control. In panels B and D, “optimal ranges” are deﬁned for systolic and diastolic blood
, and the risk gradient comparing 6 versus 0 to 2 RFs in control is steeper. CI ¼ conﬁdence
FIGURE 2 Hazard Associated With Individual RFs Out of Control/Out of Target Range
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Multivariable-adjusted hazard ratios (HRs) (95% conﬁdence intervals [CIs]) are shown for individual risk factors (RFs) out of target range. RFs in
control/in target range for this exploratory analysis were deﬁned as: non–high-density lipoprotein cholesterol (non-HDL-C) <130 mg/dl,
triglycerides (TG) <150 mg/dl, 110 mm Hg < systolic blood pressure (SBP) <140 mm Hg, diastolic blood pressure (DBP) <80 mm Hg,
6.5% < glycosylated hemoglobin (HbA1c) < 7.5%, and no smoking. Cox models were adjusted for number of total lesions, abnormal
left ventricular ejection fraction, Myocardial Jeopardy Index, prior revascularization, age, sex, race/ethnicity, country, and trial strata.
MI ¼ myocardial infarction.
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772to link observed beneﬁts to achievement of speciﬁc
treatment targets. Howard et al. (13) observed bene-
ﬁts of tighter cholesterol and BP targets on carotid
atherosclerosis in SANDS (Stop Atherosclerosis in
Native Diabetics Study) but acknowledged a greater
rate of adverse events associated with tighter BP
control (13). Concerns were raised about the incre-
ased mortality associated with “aggressive” treat-
ment of hyperglycemia among patients with T2DM in
ACCORD (Action to Control Cardiovascular Risk in
Diabetes Study) (9). Long-term follow-up in INVEST
(International Verapamil SR/Trandolapril Study)
suggested small but signiﬁcant increases in mortality
among patients with diabetes and CHD who achieved
systolic BP <130 mm Hg compared with less stringent
control (130 to 140 mm Hg) (14).
In the present study, the number of RFs in control
at baseline was not related to study outcomes. In
contrast, the number of RFs in control after 1 year of
comprehensive medical intervention was strongly
related to subsequent mortality and CVD events.
Potential explanations for this observation include
the potency of pharmacological interventionsinitiated after randomization (statins and antihy-
pertensive agents), which diminishes the prognostic
value of baseline RFs and greater statistical power to
show an effect of better RF control during follow-up
when more patients have good RF control. Given
that RF control at BARI 2D entry was comparable to
the U.S. population with diabetes (3), these data
suggest that, with appropriate resource allocation,
similar improvements in prognosis could be ach-
ieved among subjects with diabetes in the general
population.
Using BARI 2D treatment targets, patients with
0 to 2 RFs under control had twice the risk of mor-
tality and a 70% greater risk of death or CVD event
during follow-up compared with those who had 6
RFs under control. These analyses also suggest that
there is a plateau of beneﬁt at 5 RFs under control,
with a small increase in risk among those who had
6 RFs under control. Our exploratory analyses
(including sensitivity analyses using 2 different
ranges of “ideal” BP and HbA1c) suggest that over-
control of systolic BP, but not HbA1c, could mediate
this phenomenon.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with T2DM and coronary artery disease,
achievement of RF targets is related to cardiovascular events and
mortality.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to deﬁne optimal target levels for systolic BP and HbA1c for pa-
tients with T2DM.
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773STRENGTHS AND LIMITATIONS. BARI 2D represents
a contemporary cohort of patients with T2DM,
well characterized at baseline, with 5-year longi-
tudinal assessment of RFs, and with adjudicated
cardiovascular and mortality outcomes. Our statisti-
cal analysis has important strengths: ﬁrst, it captured
the cardiovascular and mortality risks associated with
the number of RFs below target levels over the
entire follow-up period; second, it assessed the risk
associated with changes in RF status incorporating
baseline RF status; third, it adjusted for important
confounders; and lastly, it explored the risk associ-
ated with BP and HbA1c within a target range.
We acknowledge some limitations. First, subjects
enrolled in the BARI 2D study represent a selected
population of subjects with T2DM, angiographically
documented stable CHD with revascularizable le-
sions, and myocardial ischemia who were followed
up at tertiary care centers. Second, although we ex-
pressed outcomes as a function of RF control, we
were unable to distinguish beneﬁts that accrued
through pleiotropic effects of medications used to
achieve RF control from beneﬁts that accrued due to
the actual level of each RF achieved. Finally, in our
exploratory analysis, “overcontrol” of BP was asso-
ciated with worse outcomes. Given the design of this
post-hoc analysis, we are unable to distinguish be-
tween declines in BP due to intensiﬁed treatment asopposed to declines that occurred as a consequence
of developing ill health. Our conclusion should thus
be interpreted with caution and requires veriﬁcation
in speciﬁcally designed prospective trials.
CONCLUSIONS
Protocol-guided therapy with speciﬁc treatment tar-
gets can improve control of multiple RFs, which re-
lates to survival and future clinical events among
patients with CHD and T2DM.
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